You beat me to it, I was about to post it but fort
Post# of 72440
Is anyone here the "scootto" who posted? Step up and take a bow if so. It IS a little uncomfortably close to "scott" but we'll not make assumptions.
Quote:
Scootto
Comments (135) |
I have to say, I sell in the Rheumatology/Derm marketplace and the oral DMARD Otezla is worthless. Bad GI side effects, minimal efficacy,and what little efficacy it has diminishes over time. If PLURISOL has good efficacy this stock should pop. Also, preclinical trials show its better than MTX or methotrexate, the gold standard for DMARDS and first line therapy. POP goes the Weasel BC the Weasel goes POP! Here comes $20 min a share!!!